Federal health officials have issued a national advisory warning that patients taking a widely used class of immune-modulating medications face an increased risk of severe brain and spinal cord infections from viruses transmitted by mosquitoes and ticks. The advisory was distributed through the CDC Health Alert Network and focuses on drugs that deplete or modify B cells, particularly monoclonal antibodies targeting the CD20 cell surface antigen.
The figure behind the warning is stark, with an important caveat. Among published case reports of arboviral neuroinvasive disease in patients taking anti-CD20 monoclonal antibodies, overall mortality was approximately 40 percent, and most survivors experienced long-term neurologic sequelae. Published case reports skew toward the most severe outcomes, so that number describes the reported cases rather than everyone infected.
The timing is deliberate. The CDC noted the United States had an early and strong start to this year's West Nile virus season, with many weeks of the arbovirus transmission season remaining.
The Medications Named in the Advisory
The anti-CD20 monoclonal antibodies named by the CDC include rituximab and biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and ibritumomab tiuxetan. The advisory also flags other B cell-depleting drugs such as anti-CD38 monoclonal antibodies and agents that modulate B cell function, including B cell activating factor inhibitors.
These are not niche treatments. They are used for B-cell malignancies, many autoimmune conditions, and transplant rejection. Many patients take them for years.
West Nile virus was the most common infecting arbovirus in the case reports the CDC reviewed. Less common or regionally focal viruses also caused severe disease in these patients, including eastern equine encephalitis, Powassan, Jamestown Canyon, La Crosse, Cache Valley, and Potosi viruses.
The Biology That Makes These Patients Vulnerable
The mechanism is straightforward. B cells produce antibodies, and patients on these medications, in the CDC's words, "might not form antibodies against a new infection." Without that antibody response, a virus most people clear without noticing can move into the nervous system.
That same gap creates a diagnostic problem. Standard serologic testing looks for antibodies the patient makes against the virus, so someone who cannot produce them may test negative while actively infected. These patients can also have prolonged viremia and delayed or absent antibody responses.
The CDC therefore advises clinicians to preferentially order molecular testing, such as virus-specific RT-PCR or metagenomic next-generation sequencing, which detect viral RNA in specimens including serum, plasma, cerebrospinal fluid, whole blood or tissue. Serologic testing should be ordered only for patients who are immunocompetent or receiving immunomodulating drugs that do not substantially suppress antibody production. The agency publishes a diagnostic testing algorithm for suspected West Nile virus disease.
The advisory also describes an unusual pattern from recent years. At least five patients receiving rituximab developed a chronic, neurodegenerative encephalitis progressing over months to years after infection with an orthobunyavirus, including Jamestown Canyon, Cache Valley, or Potosi virus. All died, and diagnoses were delayed because the infections went unrecognized and the pathogens were rare or unexpected, requiring specialized testing.
Households with a Patient on Immune Therapy
For families, the practical consequence is a change in how seriously ordinary summer mosquito exposure should be taken by one specific household member. There are no approved treatments, prophylactic agents, or human vaccines for the arboviral diseases endemic to the United States. Avoiding bites is the only tool available.
Standard advice therefore carries more weight for these patients. The CDC recommends EPA-registered insect repellent, loose-fitting long-sleeved shirts and pants outdoors, window and door screens or air conditioning, and treating clothing and gear with products containing 0.5 percent permethrin.
Tick precautions matter equally. The prevention guidance recommends avoiding wooded and brushy areas with high grass and leaf litter, checking clothing, body, gear, and pets when returning indoors, and showering soon after being outdoors.
Timing is also less predictable here. The CDC cautions that immunocompromised patients can have a prolonged incubation period or an atypical course and might not present with illness during the usual months when mosquitoes and ticks are active, which in the United States is May through November.
Symptoms That Warrant a Call to the Prescriber
The advisory tells the public to notify a health care provider about concerning changes, including persistent headaches, fever, body aches, weakness, loss of balance, or confusion. For a patient on one of these medications, those symptoms deserve a call rather than a wait-and-see approach.
Patients should also tell clinicians about any recent travel or exposure to mosquitoes or ticks, and remind them of the medications they are taking. That last point is the one most likely to change what testing gets ordered.
No one should stop or delay an immune-suppressing medication because of this advisory. These drugs treat serious diseases, and the CDC framed the guidance around bite prevention and earlier recognition, not changing therapy.
Patients raising this at the next infusion or neurology visit can ask two questions: whether their prescriber is aware of the advisory, and what the plan would be if they develop fever or neurologic symptoms during mosquito season.
Health departments can consult the CDC's Arboviral Diseases Branch for optimal testing approaches, and the agency has published clinical guidance for providers, as well as plain-language information for people who are immunocompromised.
Key Questions Answered
What did the CDC announce? A Health Alert Network advisory warns that patients receiving B-cell-depleting or B-cell-modulating medications face an increased risk of severe arboviral neuroinvasive disease.
Which drugs are involved? Anti-CD20 monoclonal antibodies, including rituximab and biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and ibritumomab tiuxetan, plus other agents that deplete or modulate B cell function.
How serious is the risk? In published case reports of arboviral neuroinvasive disease among patients on anti-CD20 therapy, mortality was approximately 40 percent, and most survivors had lasting neurologic damage.
Why can testing miss these infections? Standard serologic testing looks for antibodies the patient produces. Patients on these drugs may not produce them, so the CDC recommends molecular testing that detects viral RNA.
Should patients stop their medication? No. These drugs treat cancer, autoimmune disease and transplant rejection. The advisory is about bite prevention and earlier recognition, not stopping therapy.
What prevention steps does the CDC recommend? EPA-registered repellent, long sleeves and pants, screens or air conditioning, permethrin-treated clothing and gear, avoiding tick habitat, and checking for ticks after being outdoors.
Which symptoms should prompt a call? Persistent headache, fever, body aches, weakness, loss of balance or confusion, particularly with recent mosquito or tick exposure.
